NASDAQ:SGP
SpyGlass Pharma, Inc.
SpyGlass Pharma, Inc. reported net income of −$39.9M in fiscal 2025. Free cash flow was −$33.5M, and the diluted share count rose 24.0%.Summary generated from SpyGlass Pharma, Inc.'s SEC filings. Latest annual report filed Mar 26, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equityn/a
Debt / equityn/a
Free cash flow−$33.5M
FCF marginn/a
Share count change+24.0%
Financials
| Item | 2024 | 2025 |
|---|---|---|
| Revenue | n/a | n/a |
| Operating income | −27 | −41 |
| Net income | −29 | −40 |
| Free cash flow | −24 | −33 |
Recent filings
- 8-KRegulation FD disclosure
Oct 1, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 6, 2026 - 8-KResults of operations and financial condition
Aug 6, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 14, 2026 - 8-KResults of operations and financial condition
May 14, 2026 - 10-KAnnual report for the fiscal year ended Dec 31, 2025
Mar 26, 2026 - 8-KResults of operations and financial condition
Mar 26, 2026 - 8-KOther events
Mar 9, 2026